Balyasny Asset Management
ADCT icon

Balyasny Asset Management’s ADC Therapeutics ADCT Stock Holding History

Balyasny Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-77,947
Closed -$292K – 2960
2026
Q1 		$292K Buy
+77,947
New +$307K ﹤0.01% 2568
2024
Q2 		– Sell
-23,765
Closed -$107K – 2514
2024
Q1 		$107K Buy
+23,765
New +$87.7K ﹤0.01% 2489
2022
Q3 		– Sell
-86,100
Closed -$684K – 2808
2022
Q2 		$684K Buy
+86,100
New +$815K ﹤0.01% 1889

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management's ADCT Position: Q2 2026 in Review

Balyasny Asset Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 77,947 shares — an estimated $292K sold.

Balyasny Asset Management first reported a position in ADCT in Q2 2022 and held it in 3 quarters. The position peaked at $684K in Q2 2022. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Balyasny Asset Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 77,947 ADC Therapeutics shares in Q2 2026, an estimated $292K.
  • Balyasny Asset Management first reported a position in ADC Therapeutics in Q2 2022 and held it in 3 quarters.
  • Balyasny Asset Management's ADC Therapeutics position peaked at $684K in Q2 2022.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.